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To the editor
I read with great interest the recent article by Barasch et al in a recent issue of your 
journal.1 The article is highly thought-provoking. Interestingly, the past few years have 
seen the emergence of a number of novel clinical applications of palifermin, in addition 
to its use in oral mucositis and graft versus host disease.
For instance, palifermin gene therapy attenuates the symptoms and enzymatic 
changes seen in ulcerative colitis, resulting in decreased expression of tumor necro-
sis factor alpha and increased expression of Ki67 and keratinocyte growth factor 
receptor, thereby ameliorating the changes in the colon seen in ulcerative colitis.2 
Similarly, a single application of palifermin before radiation therapy significantly 
ameliorates radiotherapy-induced functional deterioration in bladder tissue.3 In fact, 
Czibere et al have recently reported successful management of severe hemorrhagic 
cystitis (that developed as a consequence of stem cell transplantation) with palif-
ermin therapy.4
Further, palifermin reduces the duration of dysphagia, as well as the incidence of 
grade 2 dysphagia, in patients receiving concurrent chemotherapy and radiotherapy 
for thoracic malignancies, such as advanced lung carcinoma.5 Similarly, preadmini-
stration of palifermin markedly decreases diarrhea following administration of agents 
such as irinotecan.6
The above examples clearly illustrate the significant immunomodulatory potency of 
palifermin. Further large-scale studies are needed to elaborate further and investigate 
fully these potential uses of palifermin.
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